Insider Transactions

Samuel Di Piazza, a director at Warner Bros. Discovery (WBD), recently bought 17,346 shares. The purchase increased his position by 12%, and came to a total cost of $197,918. This is the first insider buy since November, when the company’s International President bought 58,000 shares for over $535,000. There have been a mix of insider buys and sells over the past year, with the biggest move coming from a major holder who sold 10 million shares. In total, Warner Bros. Discovery insiders ...
Read More About This

Robin Washington, a director at Salesforce (CRM), recently bought 1,695 shares. The purchase increased her stake by 4% and came to a total cost of $499,355. This marks the first insider buy since last June, when another director bought 2,050 shares, also for about $500,000. Otherwise, company insiders, including the company's CFO and COO, have been substantial sellers of shares at higher prices. Most of the sales have occurred following the exercise of stock options. Overall, Salesforce insiders own 3% of shares. The ...
Read More About This

David Farr, director at International Business Machines (IBM), recently bought 1,200 shares. The buy increased his stake by 17%, and came to total cost of $298,800. This marks the first insider buy since last November, when another company director bought 936 shares at a cost of just over $197,000, representing an initial stake. Going further back, there were two small insider sales from SVPs in 2024. This constitutes all insider activity over the past two years. Overall, IBM insiders own 0.4% of ...
Read More About This

Carles Hernandez, a director at PG&E Corp. (PCG), recently bought 3,142 shares. The buy increased his position by 10%, and came to a total cost of $49,989. Another company director also bought $50,000 on the same day, and two additional directors bought shares in the prior week. Going back further, company insiders were sellers of shares, including three sales from the company CEO. Overall, PG&E insiders own 2.7% of shares. The power and gas utility is down 4% over the past year, far ...
Read More About This

Franklin Myers, a director at HF Sinclair Corp (DINO), recently bought 5,000 shares. The buy increased his stake by 3%, and came to a total cost of $178,314. Myers was a repeat buyer throughout 2024, with buys in the $105,000 to $373,000 range. In the past few months, the company CEO and CFO have also been buyers of shares around the same price. The last insider sales occurred in early 2024. Overall, HF Sinclair insiders own 9.1% of shares. The oil and gas ...
Read More About This

Nancy Benacci, a director at Cincinnati Financial (CINF), recently bought 1,000 shares. The buy increased her stake by 15%, and came to a total cost of $136,160. This marks the first insider buy of 2025. Over the past two years, insiders were mostly buyers of shares, although one company director with over 1.1 million shares has been lightening his position. There have been no trades from company executives over the past two years. Overall, insiders at the property and casualty insurance company ...
Read More About This

Robert Eifler, President and CEO of Noble Corp (NE) recently bought 12,568 shares. The buy increased his position by 1%, and came to a total cost of $350,019. He was joined by the company CFO, who bought 8,000 shares for just over $223,250, and who increased his position by 3%. A company director also bought 8,992 shares, increasing his stake by 31%. Going further back, insiders have been slight sellers of shares at higher prices. Overall, Noble Corp insiders own 21.4% of ...
Read More About This

Christopher Boerner, CEO of Bristol Myers Squibb (BMY), recently bought 2,000 shares. The buy increased his stake by 2%, and came to a total cost of $110,096. The CEO was also a buyer in late 2023 on multiple occasions. The latest buy came a week after a company EVP bought 1,823 shares, paying $100,000 for doing so. Going further back, company insiders have been net buyers since late 2023, and sellers earlier in 2023 at much higher share prices. Overall, Bristol Myers ...
Read More About This